Skip to main content
Top
Published in: Cardiovascular Ultrasound 1/2015

Open Access 01-12-2015 | Research

The beneficial effects of TAVI in mitral insufficiency

Authors: Marco Fabio Costantino, Ernesta Dores, Pasquale Innelli, Antonella Matera, Vincenza Santillo, Roberto Violini, Rosario Fiorilli, GianGiuseppe Cappabianca, Nicola Marraudino, Eugenio Picano, Giandomenico Tarsia

Published in: Cardiovascular Ultrasound | Issue 1/2015

Login to get access

Abstract

Background

Previous studies have suggested that concomitant mitral regurgitation (MR) is a risk factor for acute transcatheter aortic valve implantation (TAVI) failure, but may improve afterwards. Aim of this study was to assess the prevalence, clinical meaning and modifications of MR in patients undergoing TAVI.

Methods

In a retrospective, two-center (Potenza-San Carlo and Roma- San Camillo) study, from January 2010 to June 2014 we enrolled 165 consecutive patients (age =80 ± 5 years, 74 males, Ejection Fraction 51 ± 9 %) referred for TAVI with either Medtronic Core-ReValving System (in 114 patients, 69 %) or balloon-expandable Edwards SAPIEN/SAPIEN XT (in 51 patients, 31 %). All patients underwent TTE and TEE assessment of MR (from 1, mild to 4 = severe according to ESC latest guidelines) with core lab reading by a single observer blinded to patient identity and status. Assessment was performed at baseline (24 h prior to intervention) and at 1, 6, 12 and 24 months.

Results

Mild-to-Moderate MR (grade 1–2) was present in 137 patients and Moderate-to-Severe MR (grade 3–4) was present in 28 patients. No significant differences were seen comparing perioperative mortality and morbidity between the two groups. In the group of preoperative MR grade 3–4 the mean decrease from MR pre-TAVI to MR at 1 month post-TAVI was 0.464 (p < 0.0001) and this improvement was persistent at 6 months (p < 0.0001) and at 12 months (p < 0.0001), with partial benefit loss at 1 and 2 years. The mean difference from Left Atrial volume post-TAVI at 1 month was 16.5 ml (p < 0.0001) and this improvement was persistent at 12 months 12.12 ml (p < 0.0001).

Conclusions

TAVI effectively treats the aortic valve but as a beneficial by product also ameliorates concomitant MR. The presence of moderate-to-severe MR does not increase the acute risk of failure of TAVI. In successful procedures, the MR improves immediately and persistently.
Literature
1.
go back to reference Iung B, Baron G, Butchart EG, Delahaye F, Gohlke-Bärwolf C, Levang OW, et al. A prospective survey of patients with valvular heart disease in Europe: the Euro Heart Survey on Valvular Heart Disease. Eur Heart J. 2003;24:1231–43.PubMedCrossRef Iung B, Baron G, Butchart EG, Delahaye F, Gohlke-Bärwolf C, Levang OW, et al. A prospective survey of patients with valvular heart disease in Europe: the Euro Heart Survey on Valvular Heart Disease. Eur Heart J. 2003;24:1231–43.PubMedCrossRef
2.
go back to reference Ruel M, Kapila V, Price J, Kulik A, Burwash IG, Mesana TG. Natural history and predictors of outcome in patients with concomi- tant functional mitral regurgitation at the time of aortic valve replacement. Circulation. 2006;114:I541–6.PubMedCrossRef Ruel M, Kapila V, Price J, Kulik A, Burwash IG, Mesana TG. Natural history and predictors of outcome in patients with concomi- tant functional mitral regurgitation at the time of aortic valve replacement. Circulation. 2006;114:I541–6.PubMedCrossRef
3.
go back to reference Caballero-Borrego J, Gómez-Doblas JJ, Cabrera-Bueno F, García-Pinilla JM, Melero JM, Porras C, et al. Incidence, associated factors and evolution of non-severe functional mitral regurgitation in patients with severe aortic stenosis undergoing aortic valve replacement. Eur J Cardiothorac Surg. 2008;34:62–6.PubMedCrossRef Caballero-Borrego J, Gómez-Doblas JJ, Cabrera-Bueno F, García-Pinilla JM, Melero JM, Porras C, et al. Incidence, associated factors and evolution of non-severe functional mitral regurgitation in patients with severe aortic stenosis undergoing aortic valve replacement. Eur J Cardiothorac Surg. 2008;34:62–6.PubMedCrossRef
4.
go back to reference Barbanti M, Dvir D, Tan J, Webb JC. Aortic stenosis and mitral regurgitation: implications for transcatheter valve treatment. EuroIntervention. 2013;9:S69–71.PubMedCrossRef Barbanti M, Dvir D, Tan J, Webb JC. Aortic stenosis and mitral regurgitation: implications for transcatheter valve treatment. EuroIntervention. 2013;9:S69–71.PubMedCrossRef
5.
go back to reference Yiu SF, Enriquez-Sarano M, Tribouilloy C, Seward JB, Tajik AJ. Determinants of the degree of functional mitral regurgita- tion in patients with systolic left ventricular dysfunction: a quanti- tative clinical study. Circulation. 2000;102:1400–6.PubMedCrossRef Yiu SF, Enriquez-Sarano M, Tribouilloy C, Seward JB, Tajik AJ. Determinants of the degree of functional mitral regurgita- tion in patients with systolic left ventricular dysfunction: a quanti- tative clinical study. Circulation. 2000;102:1400–6.PubMedCrossRef
6.
go back to reference Kono T, Sabbah HN, Rosman H, Alam M, Jafri S, Goldstein S. Left ventricular shape is the primary determinant of functional mitral regurgitation in heart failure. J Am Coll Cardiol. 1992;20:1594–8.PubMedCrossRef Kono T, Sabbah HN, Rosman H, Alam M, Jafri S, Goldstein S. Left ventricular shape is the primary determinant of functional mitral regurgitation in heart failure. J Am Coll Cardiol. 1992;20:1594–8.PubMedCrossRef
7.
go back to reference Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363:1597e1607.CrossRef Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363:1597e1607.CrossRef
8.
go back to reference Makkar RR, Fontana GP, Jilaihawi H, Kapadia S, Pichard AD, Douglas PS, et al. Transcatheter aortic-valve replacement for inoperable severe aortic stenosis. N Engl J Med. 2012;366:1696e1704.CrossRef Makkar RR, Fontana GP, Jilaihawi H, Kapadia S, Pichard AD, Douglas PS, et al. Transcatheter aortic-valve replacement for inoperable severe aortic stenosis. N Engl J Med. 2012;366:1696e1704.CrossRef
9.
go back to reference Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med. 2011;364:2187e2198. Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med. 2011;364:2187e2198.
10.
go back to reference Kodali SK, Williams MR, Smith CR, Svensson LG, Webb JG, Makkar RR, et al. Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med. 2012;366:1686e1695.CrossRef Kodali SK, Williams MR, Smith CR, Svensson LG, Webb JG, Makkar RR, et al. Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med. 2012;366:1686e1695.CrossRef
11.
go back to reference Adams DH, Popma JJ, Reardon MJ, Yakubov SJ, Coselli JS, Deeb GM, et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med. 2014;371:967e968. Adams DH, Popma JJ, Reardon MJ, Yakubov SJ, Coselli JS, Deeb GM, et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med. 2014;371:967e968.
12.
go back to reference Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin III JP, Guyton RA, et al. 2014 AHA/ACC Guideline for the Management of pa- tients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:e57ee185. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin III JP, Guyton RA, et al. 2014 AHA/ACC Guideline for the Management of pa- tients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:e57ee185.
13.
go back to reference Popma JJ, Adams DH, Reardon MJ, Yakubov SJ, Kleiman NS, Hei-mansohn D, et al. Transcatheter aortic valve replacement using a self-expanding bioprosthesis in patients with severe aortic stenosis at extreme risk for surgery. J Am Coll Cardiol. 2014;63:1972e1981. Popma JJ, Adams DH, Reardon MJ, Yakubov SJ, Kleiman NS, Hei-mansohn D, et al. Transcatheter aortic valve replacement using a self-expanding bioprosthesis in patients with severe aortic stenosis at extreme risk for surgery. J Am Coll Cardiol. 2014;63:1972e1981.
14.
go back to reference Chakravarty T, Van Belle E, Jilaihawi H, Noheria A, Testa L, Bedogni F, et al. Meta-Analysis of the Impact of Mitral Regurgitation on Outcomes After Transcatheter Aortic Valve Implantation. Am J Cardiol. 2015;115:942e949.CrossRef Chakravarty T, Van Belle E, Jilaihawi H, Noheria A, Testa L, Bedogni F, et al. Meta-Analysis of the Impact of Mitral Regurgitation on Outcomes After Transcatheter Aortic Valve Implantation. Am J Cardiol. 2015;115:942e949.CrossRef
15.
go back to reference Barbanti M, Webb JG, Hahn RT, Feldman T, Boone RH, Smith CR, et al. Impact of preoperative moderate/severe mitral regurgitation on 2-year outcome after transcatheter and surgical aortic valve replacement: insight from the PARTNER (Placement of AoRTic TraNscathetER valve) trial Cohort A. Circulation. 2013;128:2776e2784. Barbanti M, Webb JG, Hahn RT, Feldman T, Boone RH, Smith CR, et al. Impact of preoperative moderate/severe mitral regurgitation on 2-year outcome after transcatheter and surgical aortic valve replacement: insight from the PARTNER (Placement of AoRTic TraNscathetER valve) trial Cohort A. Circulation. 2013;128:2776e2784.
16.
go back to reference Baumgartner H. One Year Outcomes After TAVI in Patients With Severe Aortic Stenosis and Moderate or Severe Mitral Regurgitation. Paris: EuroPCR; 2013. Baumgartner H. One Year Outcomes After TAVI in Patients With Severe Aortic Stenosis and Moderate or Severe Mitral Regurgitation. Paris: EuroPCR; 2013.
17.
go back to reference Bedogni F, Latib A, De Marco F, Agnifili M, Oreglia J, Pizzocri S, et al. Interplay between mitral regurgitation and transcatheter aortic valve replacement with the CoreValve Revalving System: a Multicenter Registry. Circulation. 2013;128:2145e2153.CrossRef Bedogni F, Latib A, De Marco F, Agnifili M, Oreglia J, Pizzocri S, et al. Interplay between mitral regurgitation and transcatheter aortic valve replacement with the CoreValve Revalving System: a Multicenter Registry. Circulation. 2013;128:2145e2153.CrossRef
18.
go back to reference Rück A, Settergren M, Yamasaki K. TCT-108 baseline mitral regur- gitation does not affect 30 day to two year mortality after transcatheter aortic-valve implantation (TAVI). A report on 576 patients from the Swedish TAVI Registry. J Am Coll Cardiol. 2013;62:B35.CrossRef Rück A, Settergren M, Yamasaki K. TCT-108 baseline mitral regur- gitation does not affect 30 day to two year mortality after transcatheter aortic-valve implantation (TAVI). A report on 576 patients from the Swedish TAVI Registry. J Am Coll Cardiol. 2013;62:B35.CrossRef
19.
go back to reference Toggweiler S, Boone RH, Rodes-Cabau J, Humphries KH, Lee M, Nombela-Franco L, et al. Transcatheter aortic valve replacement: outcomes of patients with moderate or severe mitral regurgitation. J Am Coll Cardiol. 2012;59:2068e2074. Toggweiler S, Boone RH, Rodes-Cabau J, Humphries KH, Lee M, Nombela-Franco L, et al. Transcatheter aortic valve replacement: outcomes of patients with moderate or severe mitral regurgitation. J Am Coll Cardiol. 2012;59:2068e2074.
20.
go back to reference Tzikas A, Piazza N, van Dalen BM, Schultz C, Geleijnse ML, van Geuns RJ, et al. Changes in mitral regurgitation after transcatheter aortic valve implantation. Catheter Cardiovasc Interv. 2010;75:43e49. Tzikas A, Piazza N, van Dalen BM, Schultz C, Geleijnse ML, van Geuns RJ, et al. Changes in mitral regurgitation after transcatheter aortic valve implantation. Catheter Cardiovasc Interv. 2010;75:43e49.
21.
go back to reference Van Belle E, Juthier F, Vincentelli A, Lung B, Eltchaninoff H, Laskar M, et al. TCT-92: Does mitral regurgitation impact the outcome of TAVI procedures? Insights from the FRANCE2 Registry. J Am Coll Cardiol. 2012;60:B29.CrossRef Van Belle E, Juthier F, Vincentelli A, Lung B, Eltchaninoff H, Laskar M, et al. TCT-92: Does mitral regurgitation impact the outcome of TAVI procedures? Insights from the FRANCE2 Registry. J Am Coll Cardiol. 2012;60:B29.CrossRef
22.
go back to reference Kappetein AP, Head SJ, Genereux P, Piazza N, van Mieghen NM, Blackstone EH, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. Eur J Cardiothorac Surg. 2012;42:S45–60.PubMedCrossRef Kappetein AP, Head SJ, Genereux P, Piazza N, van Mieghen NM, Blackstone EH, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. Eur J Cardiothorac Surg. 2012;42:S45–60.PubMedCrossRef
23.
go back to reference Lancellotti P, Moura L, Pierard LA, Agricola E, Popescu BA, Tribouilloy C, et al. European Association of Echocardiography recommendations for the assessment of valvular regurgitation. Part two: mitral and tricuspid regurgitation (native valve disease). Eur J Echocardiogr. 2010;11:307–32.PubMedCrossRef Lancellotti P, Moura L, Pierard LA, Agricola E, Popescu BA, Tribouilloy C, et al. European Association of Echocardiography recommendations for the assessment of valvular regurgitation. Part two: mitral and tricuspid regurgitation (native valve disease). Eur J Echocardiogr. 2010;11:307–32.PubMedCrossRef
24.
go back to reference De Chiara B, Moreo A, De Marco F, Musca F, Oreglia J, Lobiati E, et al. Influence of CoreValve ReValving System implantation on mitral valve function: an echocardiographic study in selected patients. Catheter Cardiovasc Interv. 2011;78:638–44.PubMedCrossRef De Chiara B, Moreo A, De Marco F, Musca F, Oreglia J, Lobiati E, et al. Influence of CoreValve ReValving System implantation on mitral valve function: an echocardiographic study in selected patients. Catheter Cardiovasc Interv. 2011;78:638–44.PubMedCrossRef
25.
go back to reference Barbanti M, Webb JG, Hahn R, Thompson C, Feldman T, Kodali S, et al. Impact of preop- erative moderate/severe mitral regurgitation on patients undergoing percutaneous and surgical aortic valve replacement: insights from the PARTNER trial. J Am Coll Cardiol. 2013;61:10S.CrossRef Barbanti M, Webb JG, Hahn R, Thompson C, Feldman T, Kodali S, et al. Impact of preop- erative moderate/severe mitral regurgitation on patients undergoing percutaneous and surgical aortic valve replacement: insights from the PARTNER trial. J Am Coll Cardiol. 2013;61:10S.CrossRef
26.
go back to reference D’Onofrio A, Gasparetto V, Napodano M, Bianco R, Tarantini G, Renier V, et al. Impact of preoperative mitral valve regurgitation on outcomes after transcatheter aortic valve implantation. Eur J Cardiothorac Surg. 2012;41:1271–6.PubMedCrossRef D’Onofrio A, Gasparetto V, Napodano M, Bianco R, Tarantini G, Renier V, et al. Impact of preoperative mitral valve regurgitation on outcomes after transcatheter aortic valve implantation. Eur J Cardiothorac Surg. 2012;41:1271–6.PubMedCrossRef
27.
go back to reference Toggweiler S, Boone RH, Rodés-Cabau J, Humphries KH, Lee M, Nombela-Franco L, et al. Transcatheter aortic valve replacement: outcomes of patients with moderate or severe mitral regurgitation. J Am Coll Cardiol. 2012;59:2068–74.PubMedCrossRef Toggweiler S, Boone RH, Rodés-Cabau J, Humphries KH, Lee M, Nombela-Franco L, et al. Transcatheter aortic valve replacement: outcomes of patients with moderate or severe mitral regurgitation. J Am Coll Cardiol. 2012;59:2068–74.PubMedCrossRef
Metadata
Title
The beneficial effects of TAVI in mitral insufficiency
Authors
Marco Fabio Costantino
Ernesta Dores
Pasquale Innelli
Antonella Matera
Vincenza Santillo
Roberto Violini
Rosario Fiorilli
GianGiuseppe Cappabianca
Nicola Marraudino
Eugenio Picano
Giandomenico Tarsia
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Cardiovascular Ultrasound / Issue 1/2015
Electronic ISSN: 1476-7120
DOI
https://doi.org/10.1186/s12947-015-0040-5

Other articles of this Issue 1/2015

Cardiovascular Ultrasound 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.